A Journey of Global Milestones in Healthcare Excellence

Intas has been consistently featured in leading media outlets for its groundbreaking contributions to healthcare and innovation. From global achievements to transformative initiatives, our journey continues to inspire and make headlines worldwide.

Press Notes

Accord BioPharma, Inc. Announces U.S. FDA Acceptance of Biologics License Application for Proposed STELARA Biosimilar

Accord Healthcare receives positive CHMP opinion for IMULDOSA, ustekinumab biosimilar to Stelara

Coherus Announces Agreement to Divest UDENYCA

FDA Approves IMULDOSA (ustekinumab-srlf), Accord BioPharma's Biosimilar to STELARA

Intas launches DCGI-approved Tofacitinib Topical (JAKi) in Auto-Immune Condition Atopic Dermatitis (AD) for Indian patients

Intas Pharmaceuticals Launches its Trastuzumab Biosimilar

Intas Pharmaceuticals Ltd and Henlius Biotech enter into Exclusive License Agreement to commercialise serplulimab

Intas Pharmaceuticals Ltd. Announces Licensing Agreement with mAbxience for Etanercept Biosimilar

Xbrane and Intas enter into a Global Licensing agreement to jointly develop Nivolumab biosimilar referencing Opdivo for markets worldwide

company-logo

Corporate Office

Intas Pharmaceuticals Ltd.

Corporate House, Near Sola Bridge, S. G.

Highway, Thaltej, Ahmedabad – 380054.

Gujarat. India.

call-icon+91 79 6157 7000

email-icongeneralqueries@intaspharma.com

Follow us on linkedin

© 2019 Intas Pharmaceuticals Ltd.

All rights reserved.